Before the First Operation: The Commercial Commitments Behind NHS Surgical Robotics
The Robotics Value Chain: MHRA, NICE, ICBs, GPOs and NHS England
In this briefing
- Introduction
- The UK market and its boundaries
- Suppliers, platforms and the installed base
- Clinical evidence and procurement timelines
- NHS commercial guidance
- Commercial payment models
- An evidence plan that reads as a commercial document
- Source of Funding and Cost of Change
- Procurement Act transition and sourcing options
- Clinical evidence and future commitments
- Looking ahead
- About the Author
- FAQs
- References
- Disclaimer
Introduction
NHS England projects 500,000 robot-assisted operations a year by 2035, up from 70,000 in 2023/24.1 Those are projections, not orders. Delivering that expansion will depend on procurement decisions and supplier commitments made well before the operations take place.
The 2025 annual report of Intuitive Surgical, a supplier on the NHS Supply Chain robotics framework, shows what that looks like from the supplier’s side: 84% of its revenue was recurring, earned from instruments, service and operating leases rather than from selling systems.2 Historical recurring revenue isn’t a commitment about the future, and the figures cover the company’s worldwide business, not NHS contracts. They do show where the money sits once a platform is installed.
Health Innovation Oxford and Thames Valley published a piece on 23 September arguing that robotic surgery is a transformation programme, not a procurement project, with evaluation designed before rollout and continued after sign-off.3 A further commercial question follows. Whatever a trust plans to evaluate, learn or change after go-live has to be possible under the contract it signed beforehand.
The UK market and its boundaries
Surgical robotics comprises several markets with different clinical use, procurement and revenue characteristics. Soft-tissue platforms support procedures across urology, colorectal surgery, gynaecology and other specialties; orthopaedic systems are associated with hip and knee reconstruction and, in some models, the supplier’s implant portfolio. Spinal and neurosurgical systems represent another procurement category. A count of surgical robots, the value of equipment contracts and the revenue generated by recurring instruments and support are therefore different measures of market size.
Grand View…
Continue with membership
The rest of this briefing is available to active CPO Insights members.
This briefing reflects the author's analysis and understanding of the market, based on professional experience and information available at the time of publication. It is provided for information and discussion and is not legal, financial, investment or other professional advice. Full disclaimer.